{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:06:51Z","timestamp":1790910411188,"version":"4.1.0"},"reference-count":208,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.pharmthera.2004.02.002","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T10:20:36Z","timestamp":1080642036000},"page":"61-85","source":"Crossref","is-referenced-by-count":140,"title":["Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis"],"prefix":"10.1016","volume":"102","author":[{"given":"Piyali","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2004.02.002_BIB1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1096\/fj.01-0272fje","article-title":"Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist","volume":"16","author":"Aavik","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/bbrc.1993.1671","article-title":"Synthesis and secretion of vascular permeability factor\/vascular endothelial growth factor by human retinal pigment epithelial cells","volume":"193","author":"Adamis","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB4","first-page":"961","article-title":"The role of angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis","volume":"17","author":"Afuwape","year":"2002","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1096\/fasebj.13.6.647","article-title":"Somatostatin controls Kaposi sarcoma tumor growth through inhibition of angiogenesis","volume":"13","author":"Albini","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0165-6147(98)01211-5","article-title":"Antiangiogenic tumor therapy: will it work?","volume":"19","author":"Augustin","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/res.89.8.645","article-title":"Tubes, branches, and pillars: the many ways of forming a new vasculature","volume":"89","author":"Augustin","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/EDR.2000.39","article-title":"Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat","volume":"1","author":"Averbukh","year":"2000","journal-title":"Int J Exp Diabetes Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB9","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/ndt\/16.10.2002","article-title":"Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats","volume":"16","author":"Bak","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB10","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","article-title":"Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney","volume":"280","author":"Balster","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/carcin\/18.6.1155","article-title":"Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis","volume":"18","author":"Banerjee","year":"1997","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB12","first-page":"253","article-title":"Overexpression of vascular endothelial growth factor 164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells","volume":"16","author":"Banerjee","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","article-title":"Somatostatin and somatostatin receptor physiology","volume":"20","author":"Barnett","year":"2003","journal-title":"Endocrine"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/jsre.1993.1167","article-title":"Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent","volume":"55","author":"Barrie","year":"1993","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB16","first-page":"709","article-title":"Identification and characterization of novel somatostatin antagonists","volume":"50","author":"Bass","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB13","first-page":"18","article-title":"Growth hormone and somatostatin in glomerular injury","volume":"12","author":"Baud","year":"1999","journal-title":"J Nephrol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-2001-15282","article-title":"Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy","volume":"33","author":"Boehm","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2249.1999.00949.x","article-title":"Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumor necrosis factor-alpha (TNF-alpha) in synovial fluid","volume":"117","author":"Bottomley","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1139\/o74-148","article-title":"Isolation of somatostatin (a somatotropin release inhibiting factor) of ovine hypothalamic origin","volume":"52","author":"Brazeau","year":"1974","journal-title":"Can J Biochem"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2004.02.002_BIB21","doi-asserted-by":"crossref","first-page":"iii71","DOI":"10.1136\/ard.60.90003.iii71","article-title":"Antagonizing angiogenesis in rheumatoid arthritis","volume":"60","author":"Brenchley","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.02.002_BIB22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/eje.0.143S003","article-title":"Somatostatin receptors and the potential use of Sandostatin to interfere with vascular remodeling","volume":"143","author":"Bruns","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB24","doi-asserted-by":"crossref","first-page":"28431","DOI":"10.1074\/jbc.M201261200","article-title":"Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration","volume":"277","author":"Buchan","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s001250050794","article-title":"Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy","volume":"40","author":"Burgos","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB26","first-page":"426","article-title":"Diabetic nephropathy","volume":"5","author":"Castellino","year":"1994","journal-title":"Curr Ther Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1046\/j.1464-5491.2000.00350.x","article-title":"Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications","volume":"17","author":"Chiarelli","year":"2000","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(84)92761-2","article-title":"Somatostatin, a potent analgesic","volume":"2","author":"Chrubasik","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.172.6.1535","article-title":"Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration","volume":"172","author":"Clauss","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0026-0495(99)90261-5","article-title":"Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus","volume":"48","author":"Clemens","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB31","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","article-title":"Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes","volume":"48","author":"Cooper","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB32","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.94.17.9343","article-title":"Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5","volume":"94","author":"Cordelier","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB33","doi-asserted-by":"crossref","first-page":"H1815","DOI":"10.1152\/ajpheart.2000.278.6.H1815","article-title":"Somatostatin receptor subtype expression and function in human vascular tissue","volume":"278","author":"Curtis","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0026-0495(96)90080-3","article-title":"The effects of the somatostatin analog octreotide on angiogenesis in vitro","volume":"45","author":"Danesi","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB35","first-page":"265","article-title":"Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995)","volume":"3","author":"Danesi","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjp.0702990","article-title":"Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro","volume":"129","author":"Dasgupta","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/bbrc.1999.0773","article-title":"Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin","volume":"259","author":"Dasgupta","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB37","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1023\/A:1018935800052","article-title":"Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability","volume":"16","author":"Dasgupta","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0024-3205(00)00476-8","article-title":"Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells in vitro","volume":"66","author":"Dasgupta","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1248\/bpb.25.29","article-title":"N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells","volume":"25","author":"Dasgupta","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2001-15286","article-title":"The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors","volume":"33","author":"Davis","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB41","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.11213","article-title":"Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis","volume":"48","author":"DeBusk","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00001622-200201000-00010","article-title":"Somatostatin and somatostatin analogues: diagnostic and therapeutic uses","volume":"14","author":"de Herder","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB42","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","article-title":"Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes","volume":"12","author":"de Vriese","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB44","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1210\/en.136.8.3444","article-title":"Effects of somatostatin on cultured human mesangial cells","volume":"136","author":"Diez-Marques","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB45","first-page":"315","article-title":"The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4","volume":"114","author":"Earp","year":"2003","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0165-5728(01)00263-6","article-title":"Intracerebroventricular administration of somatostatin prevents and attenuates adjuvant arthritis","volume":"116","author":"Elhassan","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB47","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H","article-title":"SSTR2A is the dominant receptor subtype expressed by inflammatory cells and is widely expressed and directly regulates T-cell IFN-\u03b3 release","volume":"29","author":"Elliot","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1161\/01.CIR.91.6.1689","article-title":"Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group","volume":"91","author":"Emanuelsson","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB49","first-page":"25","article-title":"The neurobiology of somatostatin","volume":"8","author":"Epelbaum","year":"1994","journal-title":"Crit Rev Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB50","first-page":"179","article-title":"The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach","volume":"52","author":"Favoni","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0928-4257(00)00206-0","article-title":"Signal transduction of somatostatin receptors negatively controlling cell proliferation","volume":"94","author":"Ferjoux","year":"2000","journal-title":"J Physiol Paris"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2004.02.002_BIB52","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1023\/A:1012446708520","article-title":"Neuroendocrine aspects of immunolymphoproliferative diseases","volume":"12","author":"Ferone","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB54","series-title":"Principles and Practice of Oncology, Vol. 1","first-page":"134","article-title":"Biology of cancer: angiogenesis","author":"Fidler","year":"2001"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB55","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/en.2002-220949","article-title":"Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities","volume":"144","author":"Florio","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB56","first-page":"S12","article-title":"Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes","volume":"60","author":"Flyvbjerg","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00285295","article-title":"Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats","volume":"32","author":"Flyvbjerg","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/ki.1992.124","article-title":"Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion","volume":"41","author":"Flyvbjerg","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB59","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2337\/diabetes.51.10.3090","article-title":"Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody","volume":"51","author":"Flyvbjerg","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB60","first-page":"1","article-title":"Angiogenesis and angiogenesis inhibition: an overview","volume":"79","author":"Folkman","year":"1997","journal-title":"Exs"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1566524033479465","article-title":"Fundamental concepts of the angiogenic process","volume":"3","author":"Folkman","year":"2003","journal-title":"Curr Mol Med"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2004.02.002_BIB63","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S1096-6374(00)90022-4","article-title":"Targeting the growth hormone axis as a therapeutic strategy in oncology","volume":"10","author":"Friend","year":"2000","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1054\/ghir.2000.0183","article-title":"Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines","volume":"11","author":"Friend","year":"2001","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/bip.10256","article-title":"Somatostatin analogs and radiopeptides in cancer therapy","volume":"66","author":"Froidevaux","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2265.2002.01619.x","article-title":"Antiangiogenic effects of somatostatin analogues","volume":"57","author":"Garcia de la Torre","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1358\/dot.2002.38.11.820138","article-title":"Somatostatin analogues as drug therapies for retinopathies","volume":"38","author":"Grant","year":"2002","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/02713689008999620","article-title":"Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells","volume":"9","author":"Grant","year":"1990","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0167-0115(93)90356-D","article-title":"Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization","volume":"48","author":"Grant","year":"1993","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF00400229","article-title":"Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor","volume":"36","author":"Grant","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1749-6632.1993.tb26221.x","article-title":"Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies","volume":"692","author":"Grant","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.23.4.504","article-title":"The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study","volume":"23","author":"Grant","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB73","first-page":"237","article-title":"Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular disease and chronic inflammation","volume":"52","author":"Griffioen","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB74","first-page":"E918","article-title":"Effect of GH\/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats","volume":"272","author":"Gronbaek","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB75","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1523-1755.1998.00720.x","article-title":"Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes","volume":"53","author":"Gronbaek","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/jsre.2001.6149","article-title":"Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL","volume":"97","author":"Gulec","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB77","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/000313480106701108","article-title":"Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation","volume":"67","author":"Gulec","year":"2001","journal-title":"Am Surg"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB78","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/JMN:18:1-2:15","article-title":"Drug design at peptide receptors: somatostatin receptor ligands","volume":"18","author":"Hannon","year":"2002","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2141.2000.01864.x","article-title":"Current status of anti-angiogenic factors","volume":"109","author":"Harris","year":"2000","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB81","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB82","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1210\/jc.87.7.3413","article-title":"IGF-I is critical for normal vascularization of the human retina","volume":"87","author":"Hellstrom","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB83","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/sj.bjp.0704396","article-title":"Anti-inflammatory effect of synthetic somatostatin analogues in the rat","volume":"134","author":"Helyes","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB84","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/exer.2001.1147","article-title":"Somatostatin analogs inhibit neonatal retinal neovascularization","volume":"74","author":"Higgins","year":"2002","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB85","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jnci\/94.12.883","article-title":"Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us","volume":"94","author":"Hlatky","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2004.02.002_BIB86","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1023\/A:1012420207244","article-title":"Somatostatin receptor subtype expression in human tumors","volume":"12","author":"Hofland","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2004.02.002_BIB87","first-page":"23","article-title":"Functional role of somatostatin receptors in neuroendocrine and immune cells","volume":"31","author":"Hofland","year":"1999","journal-title":"Ann Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0891-6632(91)90066-X","article-title":"Effect of a somatostatin analogue (SMS 201-995) on renal function and urinary protein excretion in diabetic rats","volume":"5","author":"Igarashi","year":"1991","journal-title":"J Diabet Its Complicat"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB89","first-page":"247","article-title":"Octreotide suppresses the kidney weight and glomerular hypertrophy in diabetic rats","volume":"35","author":"Iwasaki","year":"1993","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB90","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diacare.20.4.632","article-title":"Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM","volume":"20","author":"Jacobs","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB91","first-page":"404","article-title":"Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo","volume":"2","author":"Jia","year":"2003","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB92","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00432-003-0447-5","article-title":"Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts","volume":"129","author":"Jia","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02739874","article-title":"Vasculature in nontumorous hypophyses, pituitary adenomas and carcinomas: a quantitative morphological study","volume":"6","author":"Jugenburg","year":"1995","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB94","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/(SICI)1097-0215(19990812)82:4<592::AID-IJC20>3.0.CO;2-0","article-title":"Inhibition of the growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin AN-238","volume":"82","author":"Kahan","year":"1999","journal-title":"Intl J Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB95","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI117193","article-title":"Somatostatin analogues suppress the inflammatory reaction in vivo","volume":"93","author":"Karalis","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB96","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/j.1460-2075.1995.tb07051.x","article-title":"Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor","volume":"14","author":"Kaupmann","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB97","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.1073\/pnas.93.22.12513","article-title":"A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity","volume":"93","author":"Keri","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3904\/kjim.2003.18.2.65","article-title":"Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease","volume":"18","author":"Kim","year":"2003","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB98","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1677\/joe.0.1650617","article-title":"Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells","volume":"165","author":"Kim","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB99","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1530\/acta.0.1220766","article-title":"Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus","volume":"122","author":"Kirkegaard","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","article-title":"Increased expression of angiogenic growth factors in age-related maculopathy","volume":"81","author":"Kliffen","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB101","first-page":"2193","article-title":"Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study","volume":"42","author":"Klisovic","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2004.02.002_BIB102","first-page":"II60","article-title":"Angiogenesis as a target in rheumatoid arthritis","volume":"62","author":"Koch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB103","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000063822","article-title":"Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma","volume":"65","author":"Koizumi","year":"2002","journal-title":"Digestion"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB104","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/ard.61.6.573","article-title":"Long acting somatostatin analogue for the treatment of refractory RA","volume":"61","author":"Koseoglu","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB105","first-page":"309","article-title":"Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients","volume":"28","author":"Krempf","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1043-2760(02)00667-7","article-title":"Somatostatin analogs in the diagnosis and treatment of cancer","volume":"13","author":"Lamberts","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB108","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: will they fulfill old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB106","first-page":"2329","article-title":"Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration","volume":"41","author":"Lambooij","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB109","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1523-1755.2001.060002505.x","article-title":"A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse","volume":"60","author":"Landau","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1006\/bbrc.2000.2119","article-title":"Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture","volume":"268","author":"Lawnicka","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB113","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.ph.54.030192.002323","article-title":"The somatostatin receptor in the GI tract","volume":"54","author":"Lewin","year":"1992","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB114","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/jm021093t","article-title":"A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential","volume":"46","author":"Lewis","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB111","first-page":"990","article-title":"Effects of short-term treatment of somatostatin on angiogenesis of gastric carcinoma","volume":"22","author":"Li","year":"2003","journal-title":"Ai Zheng"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB115","doi-asserted-by":"crossref","first-page":"20331","DOI":"10.1074\/jbc.271.34.20331","article-title":"Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2","volume":"271","author":"Liapakis","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB116","first-page":"1089","article-title":"Development of a selective agonist at the somatostatin receptor subtype sstr1","volume":"276","author":"Liapakis","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB117","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0026-0495(96)90070-0","article-title":"Molecular and functional properties of somatostatin receptor subtypes","volume":"45","author":"Liapakis","year":"1996","journal-title":"Metabolism"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.02.002_BIB118","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.143S021","article-title":"Somatostatin receptor subtypes in human immune cells","volume":"143","author":"Lichtenauer-Kaligis","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB112","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bjo.80.2.168","article-title":"Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy","volume":"80","author":"Limb","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB119","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0039-6060(96)80037-7","article-title":"Tumor angiogenesis in pheochromocytomas and paragangliomas","volume":"120","author":"Liu","year":"1996","journal-title":"Surgery"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1024532022166","article-title":"Anti-angiogenic therapy: rationale, challenges and clinical studies","volume":"5","author":"Longo","year":"2002","journal-title":"Angiogenesis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB121","first-page":"438","article-title":"Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995","volume":"18","author":"Mallet","year":"1992","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB122","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.1780381122","article-title":"Somatostatin-induced modulation of inflammation in experimental arthritis","volume":"38","author":"Matucci-Cerinic","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"Pt. 5","key":"10.1016\/j.pharmthera.2004.02.002_BIB123","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/eye.1991.99","article-title":"Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study","volume":"5","author":"McCombe","year":"1991","journal-title":"Eye"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB124","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1021\/jm960851a","article-title":"A refined model for the somatostatin pharmacophore: conformational analysis of lanthionine-Sandostatin analogs","volume":"40","author":"Melacini","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1023369317275","article-title":"Current status and future opportunities for controlling acromegaly","volume":"5","author":"Melmed","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB126","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ijc.1223","article-title":"Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells","volume":"92","author":"Mentlein","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB127","first-page":"13","article-title":"Vascular endothelial growth factor and ocular neovascularization","volume":"151","author":"Miller","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB128","series-title":"Pathological Basis of Disease","first-page":"136","article-title":"Diseases of the immune system","author":"Mitchell","year":"2003"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB129","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0960-894X(01)00107-X","article-title":"Novel non-peptide ligands for the somatostatin sst3 receptor","volume":"11","author":"Moinet","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB130","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/art.11232","article-title":"Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis","volume":"48","author":"Mould","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2004.02.002_BIB131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000049163","article-title":"Somatostatin, its receptors and analogs, in lung cancer","volume":"47","author":"O'Byrne","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB133","doi-asserted-by":"crossref","first-page":"15186","DOI":"10.1074\/jbc.274.21.15186","article-title":"sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1","volume":"274","author":"Pages","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB132","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1009229508096","article-title":"Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target","volume":"2","author":"Paleolog","year":"1998","journal-title":"Angiogenesis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB134","unstructured":"Papadaki, T., Vasilaki, A., Tsilimbaris, M., Pallikaris, I., & Thermos, K. (2002). Somatostatin regulates nitric oxide production in human retinal pigment epithelium (RPE) cell cultures. Paper presented at conference of the Association for Research for Vision and Opthalmology (abstract 4584)."},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB135","first-page":"578","article-title":"Somatostatin analogs in rheumatoid arthritis and other inflammatory and immune-mediated conditions","volume":"4","author":"Paran","year":"2003","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB136","first-page":"888","article-title":"A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis","volume":"60","author":"Paran","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB137","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF03350317","article-title":"Molecular pharmacology of somatostatin receptor subtypes","volume":"20","author":"Patel","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB138","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB139","first-page":"1148","article-title":"Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis","volume":"116","author":"Patel","year":"1994","journal-title":"Surgery"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB140","first-page":"2996","article-title":"Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analog of somatostatin AN-238","volume":"60","author":"Plonowski","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB141","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1021\/jm0108449","article-title":"Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity","volume":"44","author":"Poitout","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB142","doi-asserted-by":"crossref","first-page":"40601","DOI":"10.1074\/jbc.M306510200","article-title":"Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity","volume":"278","author":"Pola","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB143","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3181\/00379727-217-44216","article-title":"Mechanisms of antineoplastic action of somatostatin analogs","volume":"217","author":"Pollak","year":"1998","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB144","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1022356313153","article-title":"Medical management of growth hormone-secreting pituitary adenomas","volume":"5","author":"Racine","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB145","first-page":"838","article-title":"Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides","volume":"43","author":"Raynor","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB146","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2337\/diabetes.47.6.924","article-title":"Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats","volume":"47","author":"Raz","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB147","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB148","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1530\/acta.0.1090108","article-title":"A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth","volume":"109","author":"Reubi","year":"1985","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB149","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/jc.77.5.1323","article-title":"Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta","volume":"77","author":"Reubi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB150","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ijc.2910560513","article-title":"High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction?","volume":"56","author":"Reubi","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB151","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","author":"Reubi","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB152","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0014-2999(94)90796-X","article-title":"Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis","volume":"271","author":"Reubi","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB153","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"46","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(02)02651-1","article-title":"A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors","volume":"456","author":"Reubi","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jop.1997.13.171","article-title":"Intravitreal injection of octreotide acetate","volume":"13","author":"Robertson","year":"1997","journal-title":"J Ocular Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB156","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB157","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers","volume":"275","author":"Rocheville","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB158","first-page":"745","article-title":"The role of somatostatin in the pathophysiology of rheumatoid arthritis","volume":"16","author":"Sakane","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1020679809056","article-title":"A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit","volume":"240","author":"Schiller","year":"2002","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB161","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/(SICI)1096-9098(199610)63:2<95::AID-JSO5>3.0.CO;2-J","article-title":"Angiogenesis in follicular tumors of the thyroid","volume":"63","author":"Segal","year":"1996","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB162","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1681\/ASN.V10112374","article-title":"Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice","volume":"10","author":"Segev","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB159","doi-asserted-by":"crossref","first-page":"16423","DOI":"10.1074\/jbc.274.23.16423","article-title":"Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation","volume":"274","author":"Sellers","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB163","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.265.7.888","article-title":"Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes","volume":"265","author":"Serri","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB164","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7","article-title":"Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells","volume":"76","author":"Sharma","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB165","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1210\/me.10.12.1688","article-title":"Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3","volume":"10","author":"Sharma","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB166","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1210\/me.13.1.82","article-title":"C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest","volume":"13","author":"Sharma","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB167","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1096-6374(98)80102-0","article-title":"Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin","volume":"8","author":"Spoerri","year":"1998","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB168","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-2001-15283","article-title":"Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy\u2014evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation?","volume":"33","author":"Spranger","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB169","first-page":"290","article-title":"Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity","volume":"37","author":"Stone","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB170","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0968-0896(00)00135-8","article-title":"Template-constrained cyclic peptide analogues of somatostatin: subtype-selective binding to somatostatin receptors and antiangiogenic activity","volume":"8","author":"Suich","year":"2000","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB171","first-page":"781","article-title":"Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor\u2014positive experimental colon cancers independently of their p53 status","volume":"62","author":"Szepeshazi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB204","first-page":"1141","article-title":"Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238","volume":"22","author":"Szereday","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB172","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/art.1780401206","article-title":"Modulation of synovial cell function by somatostatin in patients with rheumatoid arthritis","volume":"40","author":"Takeba","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB205","first-page":"532","article-title":"Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium","volume":"11","author":"ten Bokum","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB173","first-page":"161","article-title":"Somatostatin and somatostatin receptors in the immune system: a review","volume":"11","author":"ten Bokum","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB175","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0042-6989(03)00169-X","article-title":"Functional mapping of somatostatin receptors in the retina: a review","volume":"43","author":"Thermos","year":"2003","journal-title":"Vision Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB174","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/152091599316775","article-title":"Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility","volume":"2","author":"Thrailkill","year":"2000","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB176","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","article-title":"Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate","volume":"114","author":"Tolentino","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB177","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","article-title":"Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate","volume":"103","author":"Tolentino","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB178","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/path.1439","article-title":"Microvascular basement membranes in diabetes mellitus","volume":"200","author":"Tsilibary","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB179","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0167-0115(96)00136-X","article-title":"Somatostatin expression in human renal cortex and mesangial cells","volume":"68","author":"Turman","year":"1997","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB180","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.85.8.2931","article-title":"Role of matrix metalloproteinase 9 in pituitary tumor behavior","volume":"85","author":"Turner","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB181","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1677\/joe.0.1650475","article-title":"Angiogenesis in pituitary adenomas\u2014relationship to endocrine function, treatment and outcome","volume":"165","author":"Turner","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB182","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jc.85.3.1159","article-title":"Angiogenesis in pituitary adenomas and the normal pituitary gland","volume":"85","author":"Turner","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB183","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1056-8727(00)00063-5","article-title":"Octreotide administration in diabetic rats: effects on renal function and morphology","volume":"14","author":"Usenmez","year":"2000","journal-title":"J Diabet Its Complicat"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB184","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.1780371017","article-title":"Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis","volume":"37","author":"van Hagen","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.02.002_BIB185","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1530\/eje.0.143S043","article-title":"Somatostatin and somatostatin receptors in retinal diseases","volume":"143","author":"van Hagen","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB186","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0898-6568(01)00194-2","article-title":"The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases","volume":"13","author":"Vantus","year":"2001","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB187","first-page":"83","article-title":"Immunolocalization of vascular endothelial growth factor in the GH3 cell line","volume":"300","author":"Vidal","year":"2000","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB188","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s004280000373","article-title":"Microvessel density in pituitary adenomas and carcinomas","volume":"438","author":"Vidal","year":"2001","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB189","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/01.CIR.96.5.1482","article-title":"Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study","volume":"96","author":"von Essen","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB190","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB191","first-page":"19","article-title":"Inhibition of human gastric cancer metastasis by octreotide in vitro and in vivo","volume":"82","author":"Wang","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB192","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1054\/bjoc.2001.1881","article-title":"Growing vascular endothelial cells express somatostatin subtype 2 receptors","volume":"85","author":"Watson","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB194","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(93)90009-3","article-title":"Somatostatin analogs for diagnosis and treatment of cancer","volume":"60","author":"Weckbecker","year":"1993","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB195","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB196","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.02.002_BIB193","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1530\/eje.0.143S015","article-title":"The somatostatin immunoregulatory circuit present at sites of chronic inflammation","volume":"143","author":"Weinstock","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB206","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1182\/blood.V82.3.954.954","article-title":"Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin","volume":"82","author":"Wiedermann","year":"1993","journal-title":"Blood"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2004.02.002_BIB197","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S1096-6374(01)80009-5","article-title":"Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy","volume":"11","author":"Wilson","year":"2001","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB207","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/108497803322287691","article-title":"Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspetive","volume":"18","author":"Woltering","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB198","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0022-4804(91)90186-P","article-title":"Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane","volume":"50","author":"Woltering","year":"1991","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB199","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1005774713202","article-title":"Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action","volume":"15","author":"Woltering","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00417-002-0591-7","article-title":"Inhibition of experimental angiogenesis of cornea by somatostatin","volume":"241","author":"Wu","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB208","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jemt.10262","article-title":"Angiogenesis in pituitary adenomas","volume":"60","author":"Yamada","year":"2003","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.pharmthera.2004.02.002_BIB201","first-page":"4225","article-title":"In vitro antiangiogenic effect of Sandostatin (octreotide) on the proliferation of the placental vessels","volume":"22","author":"Zalatnai","year":"2002","journal-title":"Anticancer Res"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T18:19:37Z","timestamp":1734286777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":208,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0163725804000221"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2004.02.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}